REG - ValiRx PLC - Notice of AGM

ValiRxAnnouncement

01/07/2020 07:00

RNS Number : 6149R
  
ValiRx PLC
  
01 July 2020
  
 

VALIRX PLC
("ValiRx", the "Company" or the "Group")
 
Notice of AGM 
 
London, UK, 1 July 2020: ValiRx Plc (AIM: VAL), the clinical stage biotechnology company announces that the Notice of Annual General Meeting (the "Notice") and Form of Proxy will be sent to shareholders later today.  The Annual General Meeting will be held at 12:00 pm on 23 July 2020 at the offices of Peterhouse Capital Limited, 80 Cheapside, London, EC2V 6DZ.
 
In light of UK Government's response to the COVID-19 outbreak, which includes banning most non-essential travel and gatherings of more than two people, the Company has determined that the resolutions to be voted at the AGM shall be voted on through a poll rather than on the show of hands. The Company believes this is the best and fairest way to ensure that the votes of all shareholders can be taken into account, whilst also preventing the Company and shareholders breaching applicable regulations. Accordingly the Company encourages all shareholders to either submit their proxy form or to use the CREST Proxy Voting Service, rather than attend the meeting in person in accordance with the Company's articles of association. Whilst completion and return of the proxy form or using the CREST Proxy Voting Service would not preclude shareholders from attending, speaking or voting in person at the AGM should they so wish, shareholders are reminded that to do so would potentially be in breach of UK Government regulations in relation to the containment and control of COVID-19 and accordingly shareholders are strongly encouraged to either submit their proxy form or use the CREST Proxy Voting Service, rather than attend the AGM in person.  The deadline for receiving votes cast for the meeting is 21 July 2020.
 
The Notice includes resolutions to:-
(1)  Receive the annual report and accounts
(2)  Re-appoint Gerry Desler as a director
(3)  Re-appoint Dr Suzanne Dilly as a director.
(4)  Re-appoint Martin Lampshire as a director.
(5)  Re-appoint Dr Kevin Cox as a director
(6)  Re-appoint the auditors
(7)  Set the auditors' remuneration
(8)  Provide authority to allot share capital
(9)  Provide authority to dis-apply statutory pre-emption rights
 
Dr Suzy Dilly, Chief Executive Officer commented "Although it is disappointing to be unable to hold a physical meeting for our AGM this year, this decision is taken with the safety of shareholders and company representatives' safety in mind.  To help enhance the shareholder experience of the AGM, we encourage shareholders who would have wished to ask questions at a physical meeting to ask those questions via our communication service, Questions@valirx.com before the 17th July 2020, and we will endeavour to provide answers prior to the voting deadline for the meeting.  We look forward to a time later in the year when face to face interactions between the Company and shareholders can resume."
 
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.
*** ENDS ***
 
For more information, please contact:
 



ValiRx plc


Tel: +44 (0) 20 7073 2628
www.valirx.com




Dr Suzy Dilly, Chief Executive












 
suzanne.dilly@valirx.com














Cairn Financial Advisers LLP (Nominated Adviser) 
Liam Murray/Jo Turner/Ludovico Lazzaretti


Tel: +44 (0) 20 7213 0880




Peterhouse Capital Limited
Duncan Vasey/Lucy Williams/Eran Zucker
 


Tel: +44 (0) 20 7469 0930













Notes for Editors
About ValiRx
ValiRx is a biotechnology oncology focused company specialising in developing novel treatments for cancer and associated biomarkers.  It aims to make a significant contribution in "precision" medicine and science, namely to engineer a breakthrough into human health and well-being, through the early detection of cancer and its therapeutic intervention.
 
The Company's business model focuses on out-licensing therapeutic candidates early in the development process.  By aiming for early-stage value creation, the company reduces risk considerably while increasing the potential for realising value.  The group is already in licensing discussions with major players in the oncology field. 
 
ValiRx's two classes of drugs in development, which each have the potential for meeting hitherto unmet medical needs by existing methods, have worldwide patent filings and agreed commercial rights.   They originate or derive from World class institutions, such as Cancer Research UK and Imperial College.
 
Until recently, cancer treatments relied on non-specific agents, such as chemotherapy.  With the development of target-based agents, primed to attack cancer cells only, less toxic and more effective treatments are now possible.  New drugs in this group-such as those in ValiRx's pipeline-promise to greatly improve outcomes for cancer patients. 
 
The Company listed on the AIM Market of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
  END
 
 
NOASDLFWSESSELM